Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Br J Ophthalmol
2022 Mar 01;1063:403-408. doi: 10.1136/bjophthalmol-2020-317712.
Show Gene links
Show Anatomy links
Randomised study evaluating the pharmacodynamics of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
Kubota R
,
Birch DG
,
Gregory JK
,
Koester JM
.
???displayArticle.abstract???
BACKGROUND/AIMS: Stargardt disease is a rare, inherited, degenerative disease of the retina that is the most common type of hereditary macular dystrophy. Currently, no approved treatments for the disease exist. The purpose of this study was to characterise the pharmacodynamics of emixustat, an orally available small molecule that targets the retinal pigment epithelium-specific 65 kDa protein (RPE65), in subjects with macular atrophy secondary to Stargardt disease.
METHODS: In this multicentre study conducted at six study sites in the USA, 23 subjects with macular atrophy secondary to Stargardt disease were randomised to one of three doses of daily emixustat (2.5 mg, 5 mg or 10 mg) and treated for 1 month. The primary outcome was the suppression of the rod b-wave recovery rate on electroretinography after photobleaching, which is an indirect measure of RPE65 inhibition.
RESULTS: Subjects who received 10 mg emixustat showed near-complete suppression of the rod b-wave amplitude recovery rate postphotobleaching (mean=91.86%, median=96.69%), whereas those who received 5 mg showed moderate suppression (mean=52.2%, median=68.0%). No effect was observed for subjects who received 2.5 mg emixustat (mean=-3.31%, median=-12.23%). The adverse event profile was consistent with prior studies in other patient populations and consisted primarily of ocular adverse events likely related to RPE65 inhibition.
CONCLUSION: This study demonstrated dose-dependent suppression of rod b-wave amplitude recovery postphotobleaching, confirming emixustat's biological activity in patients with Stargardt disease. These findings informed dose selection for a 24-month phase 3 trial (SeaSTAR Study) that is now comparing emixustat to placebo in the treatment of Stargardt disease-associated macular atrophy.
Figure 2. Mean±SE of the mean rod b-wave amplitudes prior to photobleaching and then over a 30 min period postbleaching at (A) baseline, prior to emixustat treatment and (B) after 1 month of daily treatment with emixustat.
BONTING,
The rhodopsin cycle in the developing vertebrate retina. I. Relation of rhodopsin content, electroretinogram and rod structure in the rat.
1961, Pubmed
BONTING,
The rhodopsin cycle in the developing vertebrate retina. I. Relation of rhodopsin content, electroretinogram and rod structure in the rat.
1961,
Pubmed
BROWN,
Localization of origins of electroretinogram components by intraretinal recording in the intact cat eye.
1961,
Pubmed
Bavik,
Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity.
2015,
Pubmed
Birch,
Quantitative electroretinogram measures of phototransduction in cone and rod photoreceptors: normal aging, progression with disease, and test-retest variability.
2002,
Pubmed
Braun,
Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease.
2013,
Pubmed
Briggs,
Mutations in ABCR (ABCA4) in patients with Stargardt macular degeneration or cone-rod degeneration.
2001,
Pubmed
Cideciyan,
ABCA4 disease progression and a proposed strategy for gene therapy.
2009,
Pubmed
Cideciyan,
Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations.
2007,
Pubmed
Dugel,
Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration.
2015,
Pubmed
Grover,
Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease.
2003,
Pubmed
Kubota,
Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases.
2020,
Pubmed
Kubota,
Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator.
2012,
Pubmed
Kubota,
Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers.
2014,
Pubmed
Kuehlewein,
COMPARISON OF MANUAL AND SEMIAUTOMATED FUNDUS AUTOFLUORESCENCE ANALYSIS OF MACULAR ATROPHY IN STARGARDT DISEASE PHENOTYPE.
2016,
Pubmed
Lee,
Relationships among visual cycle retinoids, rhodopsin phosphorylation, and phototransduction in mouse eyes during light and dark adaptation.
2010,
Pubmed
Lois,
Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus.
2001,
Pubmed
Mata,
Isomerization and oxidation of vitamin a in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight.
2002,
Pubmed
Molday,
The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration.
2009,
Pubmed
Rivera,
A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration.
2000,
Pubmed
Rosenfeld,
Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
2018,
Pubmed
Sato,
cis Retinol oxidation regulates photoreceptor access to the retina visual cycle and cone pigment regeneration.
2016,
Pubmed
Strauss,
Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1).
2019,
Pubmed
Strauss,
Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
2017,
Pubmed
Strauss,
Comparison of Short-Wavelength Reduced-Illuminance and Conventional Autofluorescence Imaging in Stargardt Macular Dystrophy.
2016,
Pubmed
Strauss,
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
2016,
Pubmed
Tanna,
Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options.
2017,
Pubmed
Zernant,
Analysis of the ABCA4 genomic locus in Stargardt disease.
2014,
Pubmed
